The CHS treatment market is expected to grow from USD 9,836.85 million in 2023 to USD 15,748.92 million by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 6.06%.
Current therapeutic approaches primarily include corticosteroids to manage inflammation, gabapentinoids like gabapentin to adjust aberrant pathways, speech pathology interventions to address laryngeal dysfunction, and mucoactive agents.
Key drivers include the global growth in chronic cough and CHS prevalence, demographic trends putting more people at risk, the severe quality of life impact driving demand, and insurance adjustments to improve affordability and accessibility of CHS treatments.
Despite current treatment efforts, efficacy remains limited with most patients continuing to experience cough symptoms. Industry leaders are engaged in creating novel targeted therapies like P2X3 antagonists and TRPV1 antagonists to alter the dysfunctional cough reflex arc more effectively.